Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?

Table 6

Overall mortality-free survival and overall survival by therapeutic modality, adapted from Löppenberg et al. (2016) [14].

Therapeutic modality	3-year OM-FS rate (%)	3-year OS rate (%)
TP	50,0
NLT	48,0
NLT + ADT		48,0
LT	63,0	69,0
LT + ADT		57,0
RP		78,0
BT		80,0
RT		60,0

OM-FS: overall mortality-free survival; OS: overall survival; TP: total population; NLT: no local treatment; ADT: androgen deprivation therapy; RP: radical prostatectomy; BT: brachytherapy; RT: radiotherapy.